Barclays Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price

Moderna (NASDAQ:MRNA) had its target price decreased by research analysts at Barclays from $125.00 to $111.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target would indicate a potential upside of 137.03% from the stock’s previous close.

Several other brokerages also recently commented on MRNA. TD Cowen reduced their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th. JPMorgan Chase & Co. dropped their price target on Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a report on Monday, November 4th. Bank of America lowered their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Finally, Jefferies Financial Group cut their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $93.18.

Moderna Stock Performance

NASDAQ MRNA opened at $46.83 on Friday. The firm has a market capitalization of $18.00 billion, a P/E ratio of -3.04 and a beta of 1.69. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $61.85 and its two-hundred day moving average price is $99.16. Moderna has a 1 year low of $46.57 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the business posted ($1.39) EPS. Moderna’s revenue was up 3.8% on a year-over-year basis. As a group, research analysts anticipate that Moderna will post -9.89 EPS for the current year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,184 shares of company stock worth $238,531. Company insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after buying an additional 5,129,800 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after purchasing an additional 316,552 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Moderna by 1,212.9% in the first quarter. Intech Investment Management LLC now owns 330,805 shares of the company’s stock valued at $35,251,000 after purchasing an additional 305,609 shares in the last quarter. Matrix Capital Management Company LP boosted its position in shares of Moderna by 60.8% during the first quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock valued at $77,789,000 after buying an additional 276,000 shares during the last quarter. Finally, Motley Fool Wealth Management LLC bought a new stake in Moderna during the first quarter worth $21,317,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.